After taking trifluridine and tipiracil (Lanceford), the tumor increased

Trifluridine and tipiracil (Lonsurf) is a drug for the treatment of advanced colorectal cancer and gastric cancer. The main ingredients are trifluridine and tipiracil. They inhibit tumor cell proliferation by inhibiting DNA synthesis. Since everyone's constitution and condition are different, drug reactions may vary. While it can help control tumor growth, it doesn't mean that all patients' tumors will completely shrink or stop growing.

Occasionally, tumors may temporarily increase in size during the early stages of treatment. This may be due to the therapeutic effects of the drug, also known as a treatment response. Sometimes, even with the use of trifluridine and tipiracil, tumors may progress in the short term (called "therapeutic resistance" or "progression"), some tumor types are less sensitive to drugs, or there may be drug-resistant gene mutations within the tumor; imaging examinations (such as CT or MRI) may not be sensitive enough to immediately reflect the treatment effect, and sometimes false progression is observed.

Therapeutic response is a normal physiological phenomenon that indicates that the drug is interacting with the tumor cells. This temporary tumor enlargement may be due to tumor cell death and inflammatory response, which is common during treatment. Continued use of trifluridine and tipiracil usually results in renewed tumor shrinkage, necessitating continued treatment.

Therefore, if a patient experiences an increase in trifluridine or tipiracil after using trifluridine, he first needs to contact his doctor to re-evaluate the patient's condition, possible treatment response, and adjust the treatment plan according to the specific situation, which may include changing the drug, increasing the dose, or using other treatment strategies. At the same time, regular review and close monitoring are very important.